2-sample Mendelian randomization demonstrates associations between inflammatory cytokines and bone health, suggesting further research is needed.
Circulating inflammatory factors have been implicated in various bone health outcomes, but the causal relationships remain unclear. We applied 2-sample Mendelian randomization to investigate the effects of 41 inflammatory factors on 5 bone health outcomes: osteoarthritis (OA), knee osteoarthritis (KOA), hip osteoarthritis, osteoporosis (OP), and rheumatoid arthritis (RA). We used publicly available summary statistics from genome-wide association studies of inflammatory factors and bone health outcomes. We selected genetic instruments for each inflammatory factor based on the largest available study, and performed inverse-variance weighted (IVW), Mendelian randomization-Egger, and weighted median analyses to estimate the causal effects. We also performed sensitivity analyses to assess the potential impact of horizontal pleiotropy, heterogeneity, and linkage disequilibrium. Genetically predicted IP-10 was associated with a higher odds of OA, and GROA was associated with a slightly higher odds of OP; 5 other cytokines showed inverse associations with selected outcomes in the IVW analysis (IP-10-OA, odds ratio [OR]: 1.09, 95% confidence interval [CI]: 1.01-1.17, P = .037; G-CSF-KOA, OR: 0.91, 95% CI: 0.86-0.96, P = .0006; SCF-HOA, OR: 0.90, 95% CI: 0.83-0.97, P = .004; GROA-OP,OR: 1.002,95% CI: 1.000-1.004,P = .014; MIP-1β-OP, OR: 0.999, 95% CI: 0.998-1.000, P = .031; IL-5-RA, OR: 0.91, 95% CI: 0.83-0.98, P = .019; PDGF-BB-RA, OR: 0.89, 95% CI: 0.80-0.98, P = .022). Across sensitivity analyses, we found no strong evidence of directional pleiotropy for these associations. This 2-sample Mendelian randomization study suggests several genetically predicted associations between inflammatory cytokines and bone health outcomes; however, given the small effect sizes and the limited sample sizes of the exposure genome-wide association studies, larger cytokine genome-wide association studies and independent validation are needed before clinical translation.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: